Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

키워드

참고문헌 (39)

1. Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
2. Kim SC, "Inflammatory bowel diseases in pediatric and adolescent patients : clinical, therapeutic, and psychosocial considerations", Gastroenterology, 126, pp.1550~1560 (2004)
3. 서정기, "소아기에 발병하는 염증성장질환(IBD)은 성인 IBD와 다른 질환인가? - 조기발병 소아 IBD의 역학적, 임상적, 유전학적 특성 및 치료 시 고려 사항-", Pediatric Gastroenterology, Hepatology & Nutrition, 14(1), pp.1~25 (2011), 대한소아소화기영양학회
4. Langholz E, "Inflammatory bowel diseases with onset in childhood : clinical features, morbidity, and mortality in a regional cohort", Scand J Gastroenterol, 32, pp.139~147 (1997)
5. Guariso G, "Inflammatory bowel disease developing in paediatric and adult age", J Pediatr Gastroenterol Nutr, 51, pp.698~707 (2010)
6. Kelsen JR, "Infliximab therapy in pediatric patients 7 years of age and younger", J Pediatr Gastroenterol Nutr, 59, pp.758~762 (2014)
7. Rutgeerts P, "Efficacy and safety of retreatment with anti-tumor necrosis factor antibody(infliximab)to maintain remission in Crohn’s disease", Gastroenterology, 117, pp.761~769 (1999)
8. Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn’s disease, 2014, pp.8, 1179~1207
9. Lee YM, "Infliximab"top-down"strategy is superior to"step-up"in maintaining long-term remission in the treatment of pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 60, pp.737~743 (2015)
10. Steenholdt C, "Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment : a randomised, controlled trial", Gut, 63, pp.919~927 (2014)
11. Maser EA, "Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease", Clin Gastroenterol Hepatol, 4, pp.1248~1254 (2006)
12. Turner D, "Consensus for managing acute severe ulcerative colitis in children : a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN", Am J Gastroenterol, 106, pp.574~588 (2011)
13. Hyams JS, "Development and validation of a pediatric Crohn’s disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
14. Mazumdar M, "Categorizing a prognostic variable : review of methods, code for easy implementation and applications to decision-making about cancer treatments", Stat Med, 19, pp.113~132 (2000)
15. Youden WJ, "Index for rating diagnostic tests", Cancer, 3, pp.32~35 (1950)
16. Fiocchi C, "Inflammatory bowel disease : etiology and pathogenesis", Gastroenterology, 115, pp.182~205 (1998)
17. Papadakis KA, "Role of cytokines in the pathogenesis of inflammatory bowel disease", Annu Rev Med, 51, pp.289~298 (2000)
18. Papadakis KA, "Tumor necrosis factor : biology and therapeutic inhibitors", Gastroenterology, 119, pp.1148~1157 (2000)
19. Van Deventer SJ, "Tumour necrosis factor and Crohn’s disease", Gut, 40, pp.443~448 (1997)
20. Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children", Gastroenterology, 132, pp.863~873 (2007)
21. Hyams JS, "Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease", Inflamm Bowel Dis, 15, pp.816~822 (2009)
22. Vande Casteele N, "Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice", J Clin Pharmacol, 55(Suppl 3), pp.S39~S50 (2015)
23. Ainsworth MA, "Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease", Am J Gastroenterol, 103, pp.944~948 (2008)
24. Vande Casteele N, "Antibody response to infliximab and its impact on pharmacokinetics can be transient", Am J Gastroenterol, 108, pp.962~971 (2013)
25. Seow CH, "Trough serum infliximab : a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis", Gut, 59, pp.49~54 (2010)
26. Afif W, "Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease", Am J Gastroenterol, 105, pp.1133~1139 (2010)
27. Klotz U, "Clinical pharmacokinetics and use of infliximab", Clin Pharmacokinet, 46, pp.645~660 (2007)
28. Love BL, "Azathioprine and infliximab : monotherapy or combination therapy in the treatment of Crohn’s disease", Clin Med Insights Gastroenterol, 4, pp.21~30 (2011)
29. Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)
30. Fasanmade AA, "Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease : a retrospective analysis of data from 2 phase III clinical trials", Clin Ther, 33, pp.946~964 (2011)
31. Fasanmade AA, "Serum albumin concentration : a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis", Int J Clin Pharmacol Ther, 48, pp.297~308 (2010)
32. Ohem J, "Evaluation of infliximab therapy in children with Crohn’s disease using trough levels predictors", Dig Dis, 36, pp.40~48 (2018)
33. Feagan BG, "565 Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn’s disease (CD)", Gastroenterology, 142(5 Suppl 1), pp.S-114~ (2012)
34. Vaughn BP, "209 Prospective therapeutic drug monitoring to optimizing infliximab (IFX) maintenance therapy in patients with inflammatory bowel disease (IBD)", Gastroenterology, 146(5 Suppl 1), pp.S-54~ (2014)
35. Hämäläinen A, "Serum infliximab concentrations in pediatric inflammatory bowel disease", Scand J Gastroenterol, 48, pp.35~41 (2013)
36. Ben-Horin S, "Optimizing anti-TNF treatments in inflammatory bowel disease", Autoimmun Rev, 13, pp.24~30 (2014)
37. Moss AC, "Optimizing the use of biological therapy in patients with inflammatory bowel disease", Gastroenterol Rep(Oxf), 3, pp.63~68 (2015)
38. Steenholdt C, "Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease", Scand J Gastroenterol, 46, pp.310~318 (2011)
39. Aomatsu T, "Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease", Dig Dis Sci, 56, pp.2372~2377 (2011)

관련 논문AI추천